{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:32:27Z","timestamp":1766467947765,"version":"3.40.5"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim International GmbH"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Arrhythmia"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Until the approval of dabigatran etexilate, treatment choices for stroke prevention in patients with atrial fibrillation (AF) were vitamin K antagonists (VKAs) or antiplatelet drugs. This analysis explored whether availability of non\u2010vitamin K antagonist oral anticoagulants post\u2010dabigatran approval was associated with changing treatment patterns in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Global Registry on Long\u2010Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA\u2010AF) collected data on antithrombotic therapy choices for patients with newly diagnosed nonvalvular AF at risk for stroke. In China, enrollment in phase 1 (before dabigatran approval) and phase 2 (after dabigatran approval) occurred from 2011 to 2013 and 2013 to 2014, respectively. Analyses were restricted to sites within China that contributed patients to both phases. The weighted average of the site\u2010specific results was estimated for standardization. Sensitivity analyses used multiple regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen sites participated in both phase 1 (419 patients) and phase 2 (276 patients), 76.1% and 16.0% were known to be at high risk for stroke (CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>\u2010VASc \u22652) and bleeding (HAS\u2010BLED \u22653); 55.5% were male. In phase 1, 16.7%, 61.6%, and 21.7% of patients were prescribed oral anticoagulants (OACs), antiplatelet agents, and no treatment, respectively. Respective proportions were 26.4%, 40.6%, and 33.0% in phase 2. The absolute increase in the site\u2010standardized proportion of patients prescribed OACs after dabigatran availability was 9.9% (95% confidence interval [CI]: 3.7%\u201016.0%). There was a standardized 17.3% (95% CI: \u221224.3% to \u221210.4%) absolute decrease in antiplatelet agent use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There was an increase in OAC and decrease in antiplatelet agent prescription since dabigatran availability in China. However, a large proportion of AF patients at risk for stroke remained untreated.<\/jats:p><\/jats:sec>","DOI":"10.1002\/joa3.12321","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T10:42:18Z","timestamp":1583836938000},"page":"408-416","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA\u2010AF registry"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-5957","authenticated-orcid":false,"given":"Changsheng","family":"Ma","sequence":"first","affiliation":[{"name":"Cardiology Department Atrial Fibrillation Center Beijing Anzhen Hospital Capital Medical University Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Riou Fran\u00e7a","sequence":"additional","affiliation":[{"name":"Sanofi\u2010Aventis Recherche et D\u00e9veloppement Chilly\u2010Mazarin France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihai","family":"Lu","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Sciences Department Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans\u2010Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Duisburg\u2010Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio J.","family":"Dubner","sequence":"additional","affiliation":[{"name":"Cl\u00ednica y Maternidad Suizo Argentina Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim (China) Investment Co. Ltd. Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miney","family":"Paquette","sequence":"additional","affiliation":[{"name":"Department of Medicine Boehringer Ingelheim Burlington ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Teutsch","sequence":"additional","affiliation":[{"name":"Sanofi\u2010Aventis Recherche et D\u00e9veloppement Chilly\u2010Mazarin France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis Leiden University Medical Center Leiden the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart &amp; Chest Hospital Liverpool UK"},{"name":"Aalborg Thrombosis Research Unit Department of Clinical Medicine Aalborg University Aalborg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Rothman","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Research Triangle Institute Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the GLORIA\u2010AF Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.012988"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-08-0555"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12021"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000077341"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000087149.42294.8C"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2008.10.045"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2013.03.017"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31821cd888"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-11-0948"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euw073"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.11.182"},{"key":"e_1_2_8_15_1","first-page":"162","article-title":"Guideline of stroke prevention in Chinese patients with atrial fibrillation","volume":"19","author":"Zhang Z","year":"2015","journal-title":"Chin J Cardiac Arrhyth"},{"key":"e_1_2_8_16_1","first-page":"362","article-title":"Chinese experts consensus on new oral anticoagulant in the non\u2010valvular atrial fibrillation","volume":"42","author":"Working Group on Thrombosis of Chinese Journal of Cardiology","year":"2014","journal-title":"Chin J Cardiol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.12.006"},{"key":"e_1_2_8_18_1","first-page":"32","volume-title":"Modern epidemiology","author":"Greenland S","year":"2008"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/27.1.91"},{"issue":"3","key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/00031305.1986.10475403","article-title":"Standard distance in univariate and multivariate analysis","volume":"40","author":"Flury BK","year":"1986","journal-title":"Am Stat"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.061"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000041"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joa.2017.05.004"},{"issue":"8","key":"e_1_2_8_24_1","first-page":"14","article-title":"Expert consensus on the management of atrial fibrillation in elderly population","volume":"35","author":"Writing Committee for Expert Consensus on the Management of Atrial Fibrillation in Elderly Population, Chinese Geriatric Society, Editorial board of Chinese Journal of Geriatrics","year":"2016","journal-title":"Chin J Geriatr"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.540"},{"issue":"12","key":"e_1_2_8_26_1","first-page":"899","article-title":"Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark","volume":"38","author":"Gadsboll K","year":"2017","journal-title":"Eur Heart J"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.06.055"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189495"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160756"}],"container-title":["Journal of Arrhythmia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjoa3.12321","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/joa3.12321","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/joa3.12321","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/joa3.12321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T22:24:15Z","timestamp":1722551055000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/joa3.12321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1002\/joa3.12321"],"URL":"https:\/\/doi.org\/10.1002\/joa3.12321","archive":["Portico"],"relation":{},"ISSN":["1880-4276","1883-2148"],"issn-type":[{"type":"print","value":"1880-4276"},{"type":"electronic","value":"1883-2148"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"assertion":[{"value":"2019-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}